002294 信立泰
已收盘 04-21 15:00:00
资讯
新帖
简况
图解信立泰一季报：第一季度单季净利润同比增0.03%
证券之星 · 17:44
图解信立泰一季报：第一季度单季净利润同比增0.03%
信立泰：一季度归母净利润2亿元，同比微增
美港电讯 · 13:48
信立泰：一季度归母净利润2亿元，同比微增
【A股创新药概念股走强，舒泰神、立方制药涨停】A股市场创新药概念股集体走强，其中，舒泰神20CM涨停，迪哲医药涨超13%，立方制药10CM涨停，康弘药业涨超8%，皓元医药、首药控股、苑东生物、艾迪药业、海南海药涨超6%，益方生物、信立泰涨超5%，君实生物、翰宇药业、博瑞医药、艾力斯涨超4%。
金融界 · 02:56
【A股创新药概念股走强，舒泰神、立方制药涨停】A股市场创新药概念股集体走强，其中，舒泰神20CM涨停，迪哲医药涨超13%，立方制药10CM涨停，康弘药业涨超8%，皓元医药、首药控股、苑东生物、艾迪药业、海南海药涨超6%，益方生物、信立泰涨超5%，君实生物、翰宇药业、博瑞医药、艾力斯涨超4%。
信立泰最新公告：创新基因编辑药物YOLT-101注射液临床试验申请获受理
证券之星 · 04-17
信立泰最新公告：创新基因编辑药物YOLT-101注射液临床试验申请获受理
【量价齐升榜前十：康鹏科技连续5天放量上涨，累计涨幅27.18%】截至4月15日收盘，康鹏科技量价齐升，连续5天放量上涨，累计涨幅27.18%。其余量价齐升的上涨个股还包括：红宝丽（放量上涨4天）、浙江永强（放量上涨4天）、深康佳A（放量上涨3天）、深圳华强（放量上涨3天）、川润股份（放量上涨3天）、信立泰（放量上涨3天）、大金重工（放量上涨3天）、跨境通（放量上涨3天）、东诚药业（放量上涨3天）。
金融界 · 04-15
【量价齐升榜前十：康鹏科技连续5天放量上涨，累计涨幅27.18%】截至4月15日收盘，康鹏科技量价齐升，连续5天放量上涨，累计涨幅27.18%。其余量价齐升的上涨个股还包括：红宝丽（放量上涨4天）、浙江永强（放量上涨4天）、深康佳A（放量上涨3天）、深圳华强（放量上涨3天）、川润股份（放量上涨3天）、信立泰（放量上涨3天）、大金重工（放量上涨3天）、跨境通（放量上涨3天）、东诚药业（放量上涨3天）。
华源证券：给予信立泰买入评级
证券之星 · 02-27
华源证券：给予信立泰买入评级
信立泰（002294）2月19日主力资金净买入3202.19万元
证券之星 · 02-20
信立泰（002294）2月19日主力资金净买入3202.19万元
信立泰：S086申报上市技术审评已完成
证券 · 02-18
信立泰：S086申报上市技术审评已完成
信立泰：截至1月20日，公司股东人数26,811
证券之星 · 02-18
信立泰：截至1月20日，公司股东人数26,811
信立泰（002294）2月17日主力资金净买入3191.01万元
证券之星 · 02-18
信立泰（002294）2月17日主力资金净买入3191.01万元
信立泰：S086申报上市申请后，在审核流程中，技术审评已经完成，不存在二次发补情况
互动易 · 02-18
信立泰：S086申报上市申请后，在审核流程中，技术审评已经完成，不存在二次发补情况
信立泰最新公告：SAL0140片临床试验申请获得受理
证券之星 · 02-13
信立泰最新公告：SAL0140片临床试验申请获得受理
信立泰(002294.SZ)：SAL0140药品临床试验申请获受理
智通财经 · 02-13
信立泰(002294.SZ)：SAL0140药品临床试验申请获受理
深圳信立泰药业股份有限公司申请III类会议
金融界 · 02-08
深圳信立泰药业股份有限公司申请III类会议
信立泰（002294）1月24日主力资金净卖出403.55万元
证券之星 · 01-27
信立泰（002294）1月24日主力资金净卖出403.55万元
信立泰最新公告：JK07境外临床试验取得积极中期数据
证券之星 · 01-20
信立泰最新公告：JK07境外临床试验取得积极中期数据
信立泰（002294）1月17日主力资金净买入1245.93万元
证券之星 · 01-20
信立泰（002294）1月17日主力资金净买入1245.93万元
信立泰（002294）1月16日主力资金净买入388.47万元
证券之星 · 01-17
信立泰（002294）1月16日主力资金净买入388.47万元
加载更多
公司概况
公司名称：
深圳信立泰药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-09-10
主营业务：
深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售。公司的主要产品是心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物。截至本报告期末，累计获得有效专利授权317项，其中境外授权（含港澳台地区）76项；正在申请373项，其中境外申请132项，PCT国际申请24项。公司主要在研项目103项，其中化学药71项（含创新项目48个），生物药20项（含创新项目15个），医疗器械领域12项。
发行价格：
41.98
{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":37.86,"timestamp":1745219028000,"preClose":36.05,"halted":0,"volume":13640019,"delay":0,"changeRate":0.0502,"floatShares":1115000000,"shares":1115000000,"eps":0.559,"marketStatus":"已收盘","change":1.81,"latestTime":"04-21 15:00:00","open":36.26,"high":38.26,"low":35.85,"amount":513000000,"amplitude":0.0669,"askPrice":37.88,"askSize":62,"bidPrice":37.86,"bidSize":710,"shortable":0,"etf":0,"ttmEps":0.559,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":5,"adr":0,"adjPreClose":36.05,"symbolType":"stock","openAndCloseTimeList":[[1745199000000,1745206200000],[1745211600000,1745218800000]],"highLimit":39.66,"lowLimit":32.45,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"isCdr":false,"pbRate":4.61,"roa":"--","peRate":67.728086,"roe":"7.27%","epsLYR":0.54,"committee":0.795234,"marketValue":42207000000,"turnoverRate":0.0122,"status":0,"floatMarketCap":42197000000},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2529336525","title":"图解信立泰一季报：第一季度单季净利润同比增0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529336525","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529336525?lang=zh_cn&edition=full","pubTime":"2025-04-22 01:44","pubTimestamp":1745257490,"startTime":"0","endTime":"0","summary":"证券之星消息，信立泰2025年一季报显示，公司主营收入10.62亿元，同比下降2.64%；归母净利润2.0亿元，同比上升0.03%；扣非净利润1.92亿元，同比下降4.64%；负债率15.98%，投资收益731.98万元，财务费用-374.75万元，毛利率75.32%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042200001719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"gpt_icon":0},{"id":"2529802444","title":"信立泰：一季度归母净利润2亿元，同比微增","url":"https://stock-news.laohu8.com/highlight/detail?id=2529802444","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529802444?lang=zh_cn&edition=full","pubTime":"2025-04-21 21:48","pubTimestamp":1745243319,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0183","BK0187","002294","BK0188","BK0028","BK0196","BK0239"],"gpt_icon":0},{"id":"2529812479","title":"【A股创新药概念股走强，舒泰神、立方制药涨停】A股市场创新药概念股集体走强，其中，舒泰神20CM涨停，迪哲医药涨超13%，立方制药10CM涨停，康弘药业涨超8%，皓元医药、首药控股、苑东生物、艾迪药业、海南海药涨超6%，益方生物、信立泰涨超5%，君实生物、翰宇药业、博瑞医药、艾力斯涨超4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529812479","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529812479?lang=zh_cn&edition=full","pubTime":"2025-04-21 10:56","pubTimestamp":1745204208,"startTime":"0","endTime":"0","summary":"A股市场创新药概念股集体走强，其中，舒泰神20CM涨停，迪哲医药涨超13%，立方制药10CM涨停，康弘药业涨超8%，皓元医药、首药控股、苑东生物、艾迪药业、海南海药涨超6%，益方生物、信立泰涨超5%，君实生物、翰宇药业、博瑞医药、艾力斯涨超4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/21105649700251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688513","BK0250","002294","688180","BK1515","06978","688578","002773","300199","BK0239","688131","300204","BK1161","000566","BK1574","688166","BK1583","BK0077","003020","688382","BK0197","159992","688192","688488","BK0262","BK0060","BK0046","BK0070","BK0187","399300","688197","159982","BK0216","BK0028","01877","BK0188","BK0183","BK0196","BK0146"],"gpt_icon":0},{"id":"2528792226","title":"信立泰最新公告：创新基因编辑药物YOLT-101注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2528792226","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528792226?lang=zh_cn&edition=full","pubTime":"2025-04-17 18:40","pubTimestamp":1744886424,"startTime":"0","endTime":"0","summary":"信立泰公告称，公司引进的创新基因编辑药物YOLT-101注射液临床试验申请获国家药品监督管理局受理。该药物由尧唐（南京）生物科技有限公司和信立泰共同开发，拟用于治疗家族性高胆固醇血症等疾病。该药物有望提高患者服药依从性，为家族性高胆固醇血症提供新的治疗选择。然而，药品研发周期长、风险较高，从临床到上市受到多方面因素影响，存在不确定性，短期内对公司业绩不会产生实际影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041700029799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","03347","BK1141","BK0183","BK0028","BK0188","BK1583","BK0239","BK1576","BK0187","BK0196"],"gpt_icon":0},{"id":"2527463328","title":"【量价齐升榜前十：康鹏科技连续5天放量上涨，累计涨幅27.18%】截至4月15日收盘，康鹏科技量价齐升，连续5天放量上涨，累计涨幅27.18%。其余量价齐升的上涨个股还包括：红宝丽（放量上涨4天）、浙江永强（放量上涨4天）、深康佳A（放量上涨3天）、深圳华强（放量上涨3天）、川润股份（放量上涨3天）、信立泰（放量上涨3天）、大金重工（放量上涨3天）、跨境通（放量上涨3天）、东诚药业（放量上涨3天）。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527463328","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527463328?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:42","pubTimestamp":1744706548,"startTime":"0","endTime":"0","summary":"截至4月15日收盘，康鹏科技量价齐升，连续5天放量上涨，累计涨幅27.18%。其余量价齐升的上涨个股还包括：红宝丽（放量上涨4天）、浙江永强（放量上涨4天）、深康佳A（放量上涨3天）、深圳华强（放量上涨3天）、川润股份（放量上涨3天）、信立泰（放量上涨3天）、大金重工（放量上涨3天）、跨境通（放量上涨3天）、东诚药业（放量上涨3天）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/15164249547482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","002489","BK0174","BK0229","BK0239","BK0200","BK0259","BK0118","002640","000062","BK0172","BK0214","688602","BK0138","BK0028","BK0070","BK0185","BK0107","BK0010","BK0187","002165","BK0120","BK0137","BK0077","BK0196","000016","002272","002487","BK0260","BK0250","BK0209","BK0183","BK0050","BK0012","002675","BK0126","BK0256","002294"],"gpt_icon":0},{"id":"2514844475","title":"华源证券：给予信立泰买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2514844475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514844475?lang=zh_cn&edition=full","pubTime":"2025-02-27 14:11","pubTimestamp":1740636712,"startTime":"0","endTime":"0","summary":"华源证券股份有限公司刘闯,李强近期对信立泰进行研究并发布了研究报告《慢病领域龙头，高血压/心衰市场潜力可期》，给予信立泰买入评级。我们选取海思科、恒瑞医药和贝达药业作为可比公司估值，考虑到公司创新药研发顺利推进，下游慢病市场潜力广阔，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为42.36。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022700019728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002294"],"gpt_icon":0},{"id":"2512457073","title":"信立泰（002294）2月19日主力资金净买入3202.19万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512457073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512457073?lang=zh_cn&edition=full","pubTime":"2025-02-20 09:25","pubTimestamp":1740014741,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年2月19日收盘，信立泰报收于28.01元，下跌0.04%，换手率0.62%，成交量6.88万手，成交额1.92亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入2805.4万元，融资偿还1146.26万元，融资净买入1659.15万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022000008055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0187","BK0196","BK0183","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2512589061","title":"信立泰：S086申报上市技术审评已完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2512589061","media":"证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512589061?lang=zh_cn&edition=full","pubTime":"2025-02-18 18:37","pubTimestamp":1739875020,"startTime":"0","endTime":"0","summary":"证券日报网讯信立泰2月18日在互动平台回答投资者提问时表示，S086申报上市申请后，在审核流程中，技术审评已经完成。不存在二次发补情况，目前产品仍在审评审批阶段。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-02-18/doc-inekxfhz5666703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","BK0028","BK0183","002294","BK0188","BK0239","BK0187"],"gpt_icon":0},{"id":"2512690411","title":"信立泰：截至1月20日，公司股东人数26,811","url":"https://stock-news.laohu8.com/highlight/detail?id=2512690411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512690411?lang=zh_cn&edition=full","pubTime":"2025-02-18 11:00","pubTimestamp":1739847622,"startTime":"0","endTime":"0","summary":"证券之星消息，信立泰02月18日在投资者关系平台上答复投资者关心的问题。详细信息可查阅公司年度报告和半年度报告中的相关内容。截至1月27日，公司股东人数26,924。信立泰董秘：尊敬的投资者您好，S086申报上市申请后，在审核流程中，技术审评已经完成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021800014791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0187","BK0196","BK0183","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2512690391","title":"信立泰（002294）2月17日主力资金净买入3191.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512690391","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512690391?lang=zh_cn&edition=full","pubTime":"2025-02-18 09:20","pubTimestamp":1739841636,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年2月17日收盘，信立泰报收于28.05元，下跌3.51%，换手率1.6%，成交量17.87万手，成交额5.03亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入8597.94万元，融资偿还2941.75万元，融资净买入5656.19万元，连续3日净买入累计7471.09万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021800009429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0183","BK0196","BK0188","BK0239","002294","BK0187"],"gpt_icon":0},{"id":"2512490567","title":"信立泰：S086申报上市申请后，在审核流程中，技术审评已经完成，不存在二次发补情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2512490567","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512490567?lang=zh_cn&edition=full","pubTime":"2025-02-18 09:03","pubTimestamp":1739840580,"startTime":"0","endTime":"0","summary":"有投资者向信立泰提问， 请问S086二次发补进展到哪一步了？公司回答表示，尊敬的投资者您好，S086申报上市申请后，在审核流程中，技术审评已经完成。不存在二次发补情况，目前产品仍在审评审批阶段，感谢您的关注，谢谢！\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-02-18/doc-inekwkcm4016818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0187","BK0196","002294","BK0028","BK0183","BK0239","BK0188"],"gpt_icon":0},{"id":"2511651457","title":"信立泰最新公告：SAL0140片临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2511651457","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511651457?lang=zh_cn&edition=full","pubTime":"2025-02-13 17:39","pubTimestamp":1739439565,"startTime":"0","endTime":"0","summary":"信立泰公告，公司自主研发的创新小分子药物SAL0140片临床试验申请已获得国家药品监督管理局受理。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021300032203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0028","BK1141","BK0183","BK0239","BK1576","BK0187","BK1583","03347","002294"],"gpt_icon":0},{"id":"2511471511","title":"信立泰(002294.SZ)：SAL0140药品临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2511471511","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511471511?lang=zh_cn&edition=full","pubTime":"2025-02-13 17:34","pubTimestamp":1739439283,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司收到国家药品监督管理局核准签发的受理通知书，公司自主研发的创新小分子药物SAL0140片临床试验申请获得受理。公司本次提交的申请为SAL0140用于治疗未控制高血压(包括难治性高血压)的临床试验申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1249454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK1583","BK0196","BK0028","002294","BK0188","BK1141","BK1576","BK0183","03347","BK0239"],"gpt_icon":0},{"id":"2510306266","title":"深圳信立泰药业股份有限公司申请III类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2510306266","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510306266?lang=zh_cn&edition=full","pubTime":"2025-02-09 06:58","pubTimestamp":1739055483,"startTime":"0","endTime":"0","summary":"深圳信立泰药业股份有限公司，成立于1998年，位于深圳市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，深圳信立泰药业股份有限公司共对外投资了17家企业，参与招投标项目5000次，知识产权方面有商标信息278条，专利信息261条，此外企业还拥有行政许可213个。主要股东信息显示，深圳信立泰药业股份有限公司由无限售流通股持股99.9797%、限售流通股持股0.0203%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/09065848035161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0187","BK0196","002294","BK0028","BK0183","BK4134","III","BK0239","BK0188"],"gpt_icon":0},{"id":"2506318162","title":"信立泰（002294）1月24日主力资金净卖出403.55万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506318162","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506318162?lang=zh_cn&edition=full","pubTime":"2025-01-27 09:23","pubTimestamp":1737940989,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年1月24日收盘，信立泰报收于29.86元，下跌1.39%，换手率0.43%，成交量4.75万手，成交额1.43亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入1564.27万元，融资偿还2700.42万元，融资净偿还1136.15万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012700002790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","BK0183","002294","BK0188","BK0239","BK0187"],"gpt_icon":0},{"id":"2504473569","title":"信立泰最新公告：JK07境外临床试验取得积极中期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2504473569","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504473569?lang=zh_cn&edition=full","pubTime":"2025-01-20 16:20","pubTimestamp":1737361248,"startTime":"0","endTime":"0","summary":"信立泰公告，公司收到子公司Salubris Bio通知，JK07在HFrEF和HFpEF患者的MRCT II期临床试验中获得积极中期数据。JK07的II期临床试验为随机、双盲、安慰剂对照、剂量递增研究，旨在评估其在HFrEF和HFpEF患者中的安全性和有效性。数据显示，JK07在低剂量组中显示出良好的安全性和耐受性，两组在不良事件的发生频率和严重性方面无显著差异，并初步观察到积极疗效信号。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012000020429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1141","03347","BK1583","002294","BK0188","BK0183","BK0239","BK0187","BK0028","BK0196"],"gpt_icon":0},{"id":"2504412232","title":"信立泰（002294）1月17日主力资金净买入1245.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504412232","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504412232?lang=zh_cn&edition=full","pubTime":"2025-01-20 09:18","pubTimestamp":1737335896,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年1月17日收盘，信立泰报收于30.33元，上涨2.4%，换手率0.36%，成交量4.06万手，成交额1.22亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入939.93万元，融资偿还1185.16万元，融资净偿还245.23万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012000002777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","BK0196","BK0239","BK0183","BK0188","002294"],"gpt_icon":0},{"id":"2504697622","title":"信立泰（002294）1月16日主力资金净买入388.47万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504697622","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504697622?lang=zh_cn&edition=full","pubTime":"2025-01-17 09:23","pubTimestamp":1737076980,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年1月16日收盘，信立泰报收于29.62元，下跌1.66%，换手率0.33%，成交量3.62万手，成交额1.08亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入1158.57万元，融资偿还1063.47万元，融资净买入95.1万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025011700008413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","002294","BK0188","BK0028","BK0196","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1745278370946,"stockEarnings":[{"period":"1week","weight":0.1067},{"period":"1month","weight":0.2545},{"period":"3month","weight":0.2252},{"period":"6month","weight":0.1366},{"period":"1year","weight":0.3704},{"period":"ytd","weight":0.2241}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.0151},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.0738},{"period":"ytd","weight":-0.018}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"27261人(较上一季度减少11.96%)","perCapita":"40884股","listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","registeredCapital":"111481万元","survey":" 深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售。公司的主要产品是心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物。截至本报告期末，累计获得有效专利授权317项，其中境外授权（含港澳台地区）76项；正在申请373项，其中境外申请132项，PCT国际申请24项。公司主要在研项目103项，其中化学药71项（含创新项目48个），生物药20项（含创新项目15个），医疗器械领域12项。","listedPrice":41.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}